Please login to the form below

Data by

9

Revenue 2014

Gilead Sciences

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Gilead Sciences' 2013 sales performance.

Regeneron drops RSV drug

candidates including Johnson &Johnson's lumicitabine which is in phase II testing and hopefuls from Gilead, Aviragen and Ark Bioscience, among others.

People at-risk of HIV in England could get PrEP from September

NHS England has started what it says is the world's largest single trial of a Gilead-developed therapy that protects high-risk patients from contracting HIV. ... The study of Gilead's pre-exposure prophylaxis (PrEP) therapy Truvada (emtricitabine and

Audit exposes gaps in pharma's promises on trial transparency

At the other end of the scale lie Valeant, Sigma-Tau, Gilead, Esteve, Dainippon Sunitomo, Alkermes and Abbott - all of which scored zero on the policy transparency index.

Baricitinib delay casts a pall over Lilly's results update

will be beaten to market by other rivals such as Gilead Sciences' filgotinib and AbbVie's upadacitinib ( ABT-494).

Gilead gets OK for three-in-one hep C salvage therapy in US

Gilead gets OK for three-in-one hep C salvage therapy in US. ... Gilead has also filed for the sofosbuvir, velpatasvir and voxilaprevir therapy in the EU, winning an accelerated review from the EMA in January.

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 (Next 5)

Global revenue 2014
1: Novartis
2: Pfizer
3: Roche
4: Sanofi
5: Merck & Co.
6: Johnson & Johnson
7: GlaxoSmithKline
8: AstraZeneca
9: Gilead Sciences
10: Takeda
11: AbbVie
12: Amgen
13: Teva
14: Lilly
15: Bristol-Myers Squibb
16: Bayer
17: Novo Nordisk
18: Astellas
19: Boehringer Ingelheim
20: Actavis
21: Otsuka
22: Daiichi Sankyo
23: Biogen Idec
24: Baxter
25: Merck KGaA

US revenue 2014
1: Gilead Sciences
2: Johnson & Johnson
3: Pfizer
4: Roche
5: Novartis
6: Amgen
7: Merck & Co.
8: Sanofi
9: AbbVie
10: Actavis
11: AstraZeneca
12: GlaxoSmithKline
13: Lilly
14: Bristol-Myers Squibb
15: Novo Nordisk

Cardiovascular revenue 2014
1: AstraZeneca
2: Sanofi
3: Merck & Co.
4: Daiichi Sankyo
5: Pfizer
6: Novartis
7: Bayer
8: Takeda
9: Boehringer Ingelheim
10: Astellas
11: Actelion
12: Johnson & Johnson
13: Shionogi
14: United Therapeutics
15: Bristol-Myers Squibb
16: Gilead Sciences
17: Otsuka
18: Roche
19: Lilly
20: The Medicines Company

Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com